Long-Term Ofatumumab Shows Promise for Treatment-Naive Relapsing MS

Continuous ofatumumab treatment for up to 6 years led to a sustained low annualized relapse rate in treatment-naïve patients with relapsing MS.

Related Keywords

Colorado ,United States ,Denver ,Oklahoma ,American ,Gabriel Pardo ,Novartis ,Excellence At Oklahoma Medical Research Foundation ,Sclerosis Center ,American Academy Of Neurology ,Clinicaltrials Gov Identifier ,Founding Director ,Multiple Sclerosis Center ,Oklahoma Medical Research Foundation ,